The Susceptibility of Retinal Ganglion Cells to Glutamatergic Excitotoxicity Is Type-Specific

Ian Christensen1, Bo Lu1,2, Ning Yang1,2, Kevin Huang1,2, Ping Wang1,2 and Ning Tian1,2*

1 VA Salt Lake City Health Care System, Salt Lake City, UT, United States, 2 Department of Ophthalmology & Visual Sciences, University of Utah School of Medicine, Salt Lake City, UT, United States

Retinal ganglion cells (RGCs) are the only output neurons that conduct visual signals from the eyes to the brain. RGC degeneration occurs in many retinal diseases leading to blindness and increasing evidence suggests that RGCs are susceptible to various injuries in a type-specific manner. Glutamate excitotoxicity is the pathological process by which neurons are damaged and killed by excessive stimulation of glutamate receptors and it plays a central role in the death of neurons in many CNS and retinal diseases. The purpose of this study is to characterize the susceptibility of genetically identified RGC types to the excitotoxicity induced by N-methyl-D-aspartate (NMDA). We show that the susceptibility of different types of RGCs to NMDA excitotoxicity varies significantly, in which the αRGCs are the most resistant type of RGCs to NMDA excitotoxicity while the J-RGCs are the most sensitive cells to NMDA excitotoxicity. These results strongly suggest that the differences in the genetic background of RGC types might provide valuable insights for understanding the selective susceptibility of RGCs to pathological insults and the development of a strategy to protect RGCs from death in disease conditions. In addition, our results show that RGCs lose dendrites before death and the sequence of the morphological and molecular events during RGC death suggests that the initial insult of NMDA excitotoxicity might set off a cascade of events independent of the primary insults. However, the kinetics of dendritic retraction in RGCs does not directly correlate to the susceptibility of type-specific RGC death.

Keywords: glutamate excitotoxicity, retinal ganglion cell, susceptibility, cell type specific death, retinal diseases

INTRODUCTION

In mammals, retinal ganglion cells (RGCs) are the only output neurons that conduct visual signals from the eyes to the brain and they are classified into at least 40 types using a combination of morphological, functional and genetic features (Badea and Nathans, 2004; Völgyi et al., 2005; Kim et al., 2008; Briggman and Euler, 2011; Briggman et al., 2011; Kay et al., 2011; Sanes and Masland, 2015; Baden et al., 2016; Rheaume et al., 2018). RGC degeneration occurs in many retinal diseases leading to blindness. Increasing evidence suggests that RGCs are susceptible to various injuries in a type-specific manner. For instance, in experimental models of ocular hypertension, OFF RGCs exhibited higher rates of cell death compared to ON RGCs (Della Santina et al., 2013; El-Danaf and Huberman, 2015; Ou et al., 2016), and mono-laminated ON RGCs were found to be more susceptible to elevated IOP than bi-laminated ON-OFF cells (Feng et al., 2013). Similarly, in models
of optic nerve injury, OFF RGCs were found to be more susceptible than ON RGCs, and ON sustained RGCs seem to be more susceptible than ON transient RGCs (Puyang et al., 2017). In addition, aRGCs seem to be the least susceptible RGC type to optic nerve injury in one report (Duan et al., 2015) but more susceptible RGC type in another report (Daniel et al., 2018). Recent studies have suggested that different types of RGCs could have unique gene expression patterns (Siegenthaler et al., 2009; Madsen et al., 2012; Sanes and Masland, 2015) and the same genes expressed by RGCs could protect some type of RGCs but facilitate the death of other types of RGCs (Norsworthy et al., 2017). Thus, an understanding of the type-specific vulnerability of RGCs based on their gene expression may provide insights into the molecular mechanisms of neurodegeneration and suggest novel treatment strategies.

Glutamate excitotoxicity is the pathological process by which neurons are damaged and killed by excessive stimulation of glutamate receptors, such as the N-methyl-D-aspartate (NMDA) receptor, and it plays a central role in the death of neurons in many CNS diseases (Camacho and Massieu, 2006; Hulsebosch et al., 2009). Excessive stimulation of NMDA receptors can cause excitotoxicity by allowing high levels of calcium ions (Ca$^{2+}$) to enter into cells (Maney et al., 1989). Ca$^{2+}$ influx into cells activates a number of enzymes, including phospholipases, endonucleases, and proteases. These enzymes can damage cell structures such as the cytoskeleton, cell membrane, and DNA (Stavrovskaya and Kristal, 2005; Dutta and Trapp, 2011). In addition, a calcium influx through NMDA receptors can cause apoptosis through activation of a cAMP response element binding (CREB) protein shut-off (Hardingham et al., 2002). In the retina, NMDARs are expressed by all RGCs (Fletcher et al., 2000; Zhang and Diamond, 2009) and NMDA excitotoxicity is thought to cause RGC death in several retinal diseases (Kuehn et al., 2005; Kwon et al., 2009; Almasieh et al., 2012; Tezel, 2013; Evangelho et al., 2017). However, to what extent NMDA excitotoxicity causes the death of various types of RGCs has not been systematically investigated. Accordingly, we characterized the type-specific susceptibility of RGCs to NMDA excitotoxicity using several transgenic mouse lines, which express green/yellow fluorescent protein (GFP/YFP) in specific types of RGCs.

Our results show that the susceptibility of RGCs to NMDA excitotoxicity varies significantly among different types of RGCs. Among the RGCs studied, the J-RGCs have the highest susceptibility and the aRGCs have the lowest susceptibility. These results provide for the first time a direct comparison of the susceptibility of genetically identified types of RGCs to NMDA excitotoxicity.

**MATERIALS AND METHODS**

**Animals**

The transgenic mouse strains used in this study include B6.Cg-Tg(Thy1-YFP)HJrs/J (Thy1-YFP), Tg(Thy1-EGFP)MFrs/J (Thy1-GFP), B6.129(SJL)-Kcng4<sup>Cre</sup>L<sup>/+</sup>/Jrs/J (Kcng4<sup>Cre</sup>), FSTL4-CreER (BD-CreER), JamB-CreER, TYW3, and Thy1-STOP-loxP-YFP (Thy1-Stop-YFP). The Thy1-YFP, Thy1-GFP, and Kcng4<sup>Cre</sup> mice were obtained from The Jackson Laboratory (Bar Harbor, ME, United States) (Duan et al., 2015). BD-CreER, JamB-CreER, TYW3, and Thy1-Stop-YFP mice were obtained from Dr. Joshua Sanes’ laboratory at Harvard University (Kim et al., 2008, 2010). All transgenic mice used in this study were on C57BL/6 background and were backcrossed with C57BL/6J mice for 4–5 generations in our lab. Then the BD-CreER, JamB-CreER and Kcng4<sup>Cre</sup> mice were bred into the Thy1-Stop-YFP mice to generate BD-CreER:Thy1-Stop-YFP (BD:YFP), JamB-CreER/Thr1-Stop-YFP (JamB:YFP) and Kcng4<sup>Cre</sup>/Thr1-Stop-YFP (Kcng4<sup>Cre</sup>:YFP) double transgenic mice. YFP was expressed specifically in αRGCs without any additional treatment whereas YFP was only expressed specifically in BD-RGCs or J-RGCs upon intraperitoneal (IP) injection of Tamoxifen (150 µg) at the ages of P5–15. All of these mice were viable and no significant defects in general development or overall formation of eye or retina were noticed. All animal procedures used in this study and care were preformed following protocols approved by the IACUC of the University of Utah and the IACUC of VA Salt Lake City Health Care System in compliance with PHS guidelines and with those prescribed by the Association for Research in Vision and Ophthalmology (ARVO).

**Intraocular Injection of NMDA**

The glutamate receptor agonist, NMDA, was injected intraocularly into the mice to induce *in vivo* glutamate excitotoxicity. The procedure of intraocular injection has been described previously (Xu et al., 2010). The actual dosage of the injected NMDA varied in concentration from 0.375 to 6.25 mmol/L but with a constant volume of 2 µl solution, which equivalent to 0.75–12.5 nmol of NMDA molecules. These amounts of NMDA injected into each eye are similar to those used in previous studies (Bai et al., 2013; Kimura et al., 2015; Jiang et al., 2016; Zhao et al., 2016; Ishimaru et al., 2017; Wang et al., 2018). The distribution of the solution inside the eyes was confirmed by co-injecting NMDA with Alexa Fluor<sup>TM</sup> 555 conjugated Cholera Toxin Subunit B (CTB, 0.2%, Thermo Fisher Scientific, Eugene, OR, United States) and the retinas were examined by imaging the distribution of the fluorescent signaling (data not shown). To reduce the impact of the variation of YFP expression in some of the transgenic mouse lines, we injected 2 µl NMDA solution into one eye (left) and used the non-injected contralateral eyes (right) as controls to calibrate the cellular survival rate of each mouse. In preparation for intraocular injection, the mice were anesthetized with Isoflurane (1–5% Isoflurane mixed with room air delivered in a rate between 0.8 and 0.9 L/min) through a mouse gas anesthesia head holder (David KOPF Instruments, Tujunga, CA, United States) and local application of 0.5% proparacaine hydrochloride ophthalmic solution on each eye. Glass micropipettes made from borosilicate glass using a Brown-Flaming horizontal puller with fine tip (about 10–15 µm diameter) were used for injection. The glass needle was mounted on a Nano-injection system (Nanoject II, Drummond Scientific Company, Broomall, PA, United States), which could precisely control the amount of injected solution at the nl level. The glass needle was aimed to penetrate the eyeball near its equator under a dissection microscope and a total of 2 µl...
solution was slowly injected into each eye. After the injection, the eyes were covered with 0.5% erythromycin ophthalmic ointment and the mice were placed in a clean cage sitting on a water blanket. The temperature of the water blanket was set at 33°C. Mice in this cage were continuously monitored until they completely recovered and then they were returned to their original cages. The procedures for anesthesia and intraocular injection fit the procedures approved by the IACUC of the University of Utah and the IACUC of VA Salt Lake City Health Care System.

**Primary Antibodies**

Rabbit polyclonal antibody against green fluorescent protein (GFP) conjugated with AlexaFluor 488 was purchased from Molecular Probes (Eugene, OR, United States; Catalog No. A21311). This antibody was raised against GFP isolated directly from *Aequorea victoria* and has been previously characterized by immunocytochemistry in granule cells (Overstreet-Wadiche et al., 2006), olfactory sensory neurons (Lévi and Strotmann, 2003), and hippocampal neurons that express GFP (Huang et al., 2005). Anti-active Caspase-3 antibody (anti-CASP3) was purchased from Abcam (Cambridge, MA, United States; Catalog No. ab2302). This polyclonal antibody was raised in rabbits against synthetic peptide corresponding to the N-terminus adjacent to the cleavage site of human active caspase-3 preferentially recognizes the p17 fragment of the active Caspase-3 and has been characterized by immunocytochemistry and Western blotting. Anti-RBPMS (RNA binding protein with multiple splicing) antibody was purchased from PhosphoSolutions (Aurora, CO, United States; Catalog #: 1832-RBPMS). This polyclonal antibody was raised in guinea pigs against synthetic peptide corresponding to amino acid residues from the N-terminal region of the rat RBPMS sequence conjugated to KLH. This antibody has been characterized by Western blotting and verified with immunocytochemistry on mammalian retinas (Kwong et al., 2010; Rodriguez et al., 2014). The secondary antibodies were purchased from Jackson Immune Research Laboratories (West Grove, PA, United States).

**Preparation of Retinal Whole-Mounts for Antibody Staining**

Retinal ganglion cells were imaged on whole mount retinal preparation for cell counting and dendritic morphology. The procedures for fluorescent immuno-labeling of YFP-expressing retinal neurons on retinal whole-mounts and slide preparations have been described previously in detail (Xu et al., 2010). In brief, mice were euthanized with 100% CO2 followed by cervical dislocation. Retinas were isolated and fixed in 4% paraformaldehyde (PFA) in 0.01M phosphate-buffered saline (PBS; pH 7.4) for 30 min at room temperature. Fixed retinas were washed 10 min × 3 in 0.01M PBS and incubated in blocking solution (10% normal donkey serum) at 4°C for 2 h. Next, retinas were incubated in a rabbit polyclonal anti-GFP antibody conjugated with AlexaFluor488 (1:500) for 7 days at 4°C.

In one experiment, the total RGCs were labeled by a guinea pig polyclonal anti-RBPMS antibody (1:500) and the YFP-expressing RGCs were labeled by a rabbit anti-GFP antibody conjugated with AlexaFluor 488. A Cyanine Cy3-conjugated donkey anti-guinea pig (1:400, Jackson ImmunoResearch, West Grove, PA, United States) secondary antibody was used overnight at 4°C to reveal anti-RBPMS antibody staining. In another experiment, a rabbit polyclonal anti-Caspase 3 antibody (1:150) was used to label YFP/GFP expressing RGCs actively undergoing apoptosis. An Alexa 647-conjugated donkey anti-rabbit (1:300, Jackson ImmunoResearch, West Grove, PA, United States) secondary antibody was used overnight at 4°C to reveal anti-Caspase 3 antibody staining. In this experiment, YFP/GFP signals in RGCs were not enhanced by anti-GFP antibody but the YFP/GFP expressing RGCs were still identifiable with confocal imaging. After the antibody incubation, the retinas were washed 3 × 10 min, and flat mounted on Super-Frost slides (Fisher Scientific, Pittsburgh, PA, United States) with Vectashield mounting medium for fluorescence (Vector Laboratories, Burlingame, CA, United States).

**Confocal Laser Scanning Microscopy and Image Sampling**

Fluorescent images of fixed retinal tissue were collected with a dual-channel Zeiss confocal microscope (Carl Zeiss AG, Germany) with the C-Apochromat 40× 1.2WKorr water immersion lens. Image stacks of YFP expressing RGCs in whole-mount retinas were collected at intervals of 0.5 μm. Imaris software (Bitplane, Inc., Concord, MA, United States) was used to align multi-stacks of images together, quantify the number and dendritic structure of RGCs, and adjust the intensity and contrast of images.

For image sampling, we use two different strategies for retinas with low or high densities of YFP-expressing RGCs to avoid potential bias of data sampling when the persons carrying out the histological analysis were not blinded to the treatment. For Thy1-YFP, BD-YFP and JamB-YFP mice, the YFP is expressed in a relatively low density of RGCs and the expression level varies significantly among mice (from several to several hundreds of YFP-expressing RGCs per retina) but not significantly between left and right eyes (see results in Figures 1B, 3B). Therefore, we imaged the whole retina and counted every YFP-expression RGCs in the GCL layer of these mice. The only case to exclude a mouse from data analysis is when the total number of YFP-expressing RGCs in the whole retina of the control eye is less than 10 to avoid the results to be skewed by mice with extreme low number of YFP-expressing RGCs. For TYW3 and Kcng4Cre:YFP mice, which constitutively express YFP in all W3-RGCs and αRGCs, the density of YFP+ RGCs is very high (several thousands per retina) and the expression level does not vary significantly among mice or between left and right eyes (see results in Figures 3F, 4A). We included every mouse assigned to this study for data analysis without exclusion. For image sampling, we scanned 4 squares (304 μm × 304 μm each) at 4 quarters of the retina 600 μm away from the center of optic nerve head (see Figure 3E for details). The density of YFP-expressing W3-RGCs and αRGCs of each retina was averaged from the 4 squares.
Preparation of Retinal Whole-Mounts for ex vivo Fluorescent Imaging

The time-lapse images of RGCs were taken from whole-mount retina preparations as previously described (Xu et al., 2010). Retinas of Thy1-YFP mice, BD:YFP mice and JamB:YFP mice were used for ex vivo imaging of αRGCs, BD-RGCs and J-RGCs, respectively. Retinas were isolated from Thy1-YFP, BD:YFP and JamB:YFP mice in oxygenated extracellular solution that contained (in mmol/L) NaCl 124, KCl 2.5, CaCl2 2, MgCl2 2, NaH2PO4, 1.25, NaHCO3 26, and glucose 22 (pH 7.35 with 95% O2 and 5% CO2), mounted on nitrocellulose filter paper (Millipore Corp), placed in a recording chamber and continuously perfused at 32°C. Image stacks were taken using a two-photon image system (Prairie Technologies, Inc., Middleton, WI, United States) immediately before bath application of NMDA. After 10 min of bath application of 200 nmol/L NMDA, the retinas were continuously perfused with the oxygenated extracellular solution and the cells were imaged every 1 h for 7 h.

The dendritic density of imaged cells is measured using a Sholl analysis (Xu et al., 2010) and the dendritic density after NMDA application was normalized to pre-NMDA application (0 h).

Statistical Analysis

Data are all presented as mean ± SE in the text and figures. Student t-tests are used to examine the difference between two means, K–S test is used to examine the difference between two cumulative distributions.

RESULTS

RGCs Lose Dendrites Before They Die Due to NMDA Excitotoxicity

Thy1-YFP mice have been used extensively for studying RGC morphology, physiology, development and degeneration. One potential advantage is that YFP is expressed in about 12
morphological types of RGCs in this mouse (Xu et al., 2010). To determine whether this mouse could serve as a model to study type specific RGC death in retinal diseases, we quantified the number and dendritic structure of YFP-expressing RGCs with the approach we previously used in our study (Xu et al., 2010). **Figure 1A** shows a representative image of a flat-mount retina of a Thy1-YFP mouse and a magnified area of the retina. The number and dendritic structure of the YFP-expressing RGCs are readily quantifiable using confocal imaging. **Figure 1B** shows the densities of YFP-expressing RGCs of left and right eyes of 6 Thy1-YFP mice. Although a paired t-test showed that the difference between the densities of YFP-expressing RGCs of left and right eyes is statistically insignificant (paired t-test, \( p = 0.72 \)), it seems that the density of YFP-expressing RGCs varies significantly among these mice. To determine the variation of the densities of YFP-expressing RGCs of the left and right eyes of the same mouse, we normalized the density of YFP-expressing RGCs of the left eye to that of the right eye of the same mouse. **Figure 1C** shows the normalized densities of YFP-expressing RGCs of left and right eyes of 6 Thy1-YFP mice. We then quantified the dendritic length and the size of dendritic field (DF) of YFP-expressing RGCs (**Figure 1D**) and found that the distributions of dendritic length and the size of DF of left and right eyes are not statistically different (**Figures 1E,F**, K–S tests, \( p = 0.64 \) and 0.167, respectively). Therefore, the number and dendritic properties of YFP-expressing RGCs of the left and right eyes are comparable.

Next, we tested whether the Thy1-YFP mice could be used to determine type-specific RGC death under disease conditions. Accordingly, we injected NMDA solution into the left eyes of Thy1-YFP mice and use the non-injected right eyes as controls, quantified the number of YFP-expressing RGCs and their dendritic properties, and compared the results of NMDA treated left eyes to that of non-injected right eyes. **Figure 2A** shows representative images of Thy1-YFP retinas without NMDA injection while **Figure 2B** shows a retina 1 day after NMDA injection. It is evident that many YFP-expressing RGCs died 1 day after NMDA injection and that a significant number of the surviving YFP-expressing RGCs lost dendrites (**Figures 2B2,H3**). Quantitatively, the densities of YFP-expressing RGCs are reduced to 48.1 ± 3.4% (paired t-test, \( p < 0.001 \)) and 31.6 ± 2.1% (paired t-test, \( p < 0.0001 \)) in retinas with intraocular injection of 2 \( \mu \)L 3.125 mmol/L (6.25 nmol) or 6.25 mmol/L (12.5 nmol) NMDA as compared to the non-injected right eyes (**Figures 2C1,C2**), respectively. More than 60% of the surviving YFP-expressing RGCs completely lost their dendrites with intraocular injection of 2 \( \mu \)L 6.25 mmol/L (12.5 nmol) NMDA (**Figures 2D,E**, K–S test, \( p < 0.0001 \)). In addition, among the surviving YFP-expressing RGCs with dendrites, the total dendritic length and the size of DF are significantly reduced (**Figures 2F,G**, K–S test, \( p < 0.0001 \) or \( p = 0.008 \), respectively). These results demonstrate that RGCs lose dendrites before death, which is consistent with previous reports that RGCs significantly lose or re-organize their dendrites under various disease conditions (Kuehn et al., 2005), such as glaucoma (Weber et al., 1998; Shou et al., 2003; Morgan et al., 2006; Williams et al., 2013) and optic nerve crush (ONC) (Leung et al., 2008; Weber et al., 2008).

To further test this idea, we injected NMDA into eyes of Thy1-GFP mice, in which most, if not all, RGCs are GFP-expressing, and labeled NMDA-treated retinas using an anti-CASP3 antibody to identify cells undergoing apoptosis (Pi et al., 2018). The results show that some GFP-positive cells are also CASP3-positive 3 h after NMDA injection (**Figure 2H1**), indicating that RGCs actively undergoing apoptosis are still GFP positive, while no CASP3-positive RGCs are found in non-injected eyes (data not shown). We also labeled NMDA-treated retinas of Thy1-YFP mice, in which only a small fraction of RGCs are YFP-expressing, with the anti-CASP3 antibody and found that many YFP-expressing RGCs with no dendrites are still CASP3-negative (**Figure 2H3**). These results further demonstrate that the damaged RGCs lose all dendrites before the beginning of apoptosis. Because the YFP expressed by RGCs are cytosol protein and can fill the fine remnants of dendrites of the injured RGCs (**Figure 2H3**, white arrow in the insert) as well as soma and axon, the changes in YFP-positive dendrites are likely to reflect the changes of dendritic morphology of the RGCs but not the expression level of YFP in responding to NMDA excitotoxicity. Since RGCs lose dendrites prior to death, the Thy1-YFP mice appear to be an unreliable model for studying type-specific RGC death based on dendritic morphology.

Furthermore, to determine whether the death of YFP-expressing RGCs of Thy1-YFP mice could represent the death of total RGCs induced by NMDA excitotoxicity, we compared the survival rate of YFP-expressing RGCs and total RGCs labeled by anti-RBPMS antibody (**Figures 2I1,I2**) of Thy1-YFP mice treated by intraocular injection of 2 \( \mu \)L 3.125 mmol/L (6.25 nmol) NMDA into the left eyes with non-injected right eyes. Our results show that the survival rate of YFP-expressing RGCs (50%) is significantly higher than that of anti-RBPMS antibody labeled RGCs (34.2%) (**Figure 2I3**, paired t-test, \( p = 0.002 \)), which is within the range of the results of several previous studies (Bai et al., 2013; Kimura et al., 2015; Jiang et al., 2016; Zhao et al., 2016; Ishimaru et al., 2017; Wang et al., 2018). These results suggest that the susceptibility of YFP-expressing RGCs in this mouse line is lower than the susceptibility of total RGCs. Therefore, Thy1-YFP mice seem to be an unreliable model for studying overall RGC death. Accordingly, we further employed four RGC type-specific transgenic mouse lines to study type-specific RGC death due to NMDA excitotoxicity.

The Dose-Response Relationship of NMDA Excitotoxicity Induced RGC Death

We first quantified cell death as a function of NMDA concentrations using two transgenic mouse lines, in which YFP is expressed by the BD-RGCs or W3-RGCs (Kim et al., 2010). BD-YFP mice express YFP in BD-RGCs and a small fraction of amacrine cells located in INL (Kim et al., 2010) but not displaced amacrine cells in the ganglion cell layer (GCL) (data not shown). In this study, we only included the YFP-expressing cells in the GCL. **Figure 3A** shows a representative image of a BD:YFP retina (A1) and a magnified area to show the dendritic morphology of the BD-RGCs (A2). Similar to Thy1-YFP mice, the density of YFP-expressing BD-RGCs varies significantly among mice.
However, the densities of YFP-expressing BD-RGCs of the left and right eyes of the same mice are very similar (Figure 3B). A paired t-test showed that the difference between the densities of YFP-expressing BD-RGCs of left and right eyes of BD-YFP mice is statistically insignificant. Therefore, we treated the left eye with NMDA and compared the cell density with the non-injected right eye of each mouse.

BD-RGCs seem to be very sensitive to NMDA excitotoxicity. Figure 3C shows a representative image of a BD-YFP retina 24 h after intraocular injection of 2 µL 0.75 mmol/L (1.5 nmol) NMDA. Clearly, some BD-RGCs completely lose their dendrites and somas but retain axonal remnants 24 h after NMDA injection (C2, white arrows) while a significant fraction of BD-RGCs still retain their dendrites (red arrows). We quantified the survival rates of BD-RGCs to four different NMDA concentrations and found that the density of BD-RGCs was reduced to 39.5 ± 4.3% at 2 µL 0.375 mmol/L (0.75 nmol) to 0% at 2 µL 6.25 mmol/L (12.5 nmol) as compared to the non-injected right eyes (Figure 3D). The differences between the RGC densities in all four NMDA treated groups and their respective non-injected controls are statistically significant (paired t-test).

Similarly, we quantified the densities of W3-RGCs treated with the same four NMDA concentrations and compared with their respective non-injected controls. In TYW3 mice, YFP is expressed in the W3-RGCs constitutively with a very high density and, therefore, the number of YFP-expressing W3-RGCs does not vary significantly among mice or between the left and right eyes (Figures 3E,F, paired t-test, p = 0.466). Because YFP is also...
expressed in a very small fraction of amacrine cells located in the INL but not displaced amacrine cells in the GCL in these mice (data not shown), we only included the YFP-expressing cells in the GCL. W3-RGCs were also found to be very sensitive to NMDA excitotoxicity in the GCL. W3-RGCs were also found to be very sensitive to NMDA excitotoxicity in the GCL. W3-RGCs were also found to be very sensitive to NMDA excitotoxicity in the GCL.

αRGCs Are Relatively Resistant to NMDA Excitotoxicity

αRGCs have been reported to be relatively resistant to ONC (Duan et al., 2015). We investigated whether they are also more resistant to NMDA excitotoxicity than BD-RGCs and W3-RGCs. Similar to TYW3 mice, the number of YFP-expressing αRGCs in Kcnq4Cre::YFP mice is highly consistency both between mice and between the left and right eyes (Figure 4A). In addition to αRGCs, YFP is also expressed in some bipolar cells in Kcnq4Cre::YFP mice (Duan et al., 2015). In our study, we only included the YFP-expressing cells in the GCL. Clearly, αRGCs seem to be more resistant to NMDA excitotoxicity than BD-RGCs and W3-RGCs. Many αRGCs were still visible from Kcnq4Cre::YFP retina 1 day after 2 μL 6.25 mmol/L (12.5 nmol) NMDA injection (Figure 4B). Quantitatively, intraocular injection of 2 μL 3.125 mmol/L (6.25 nmol) or 6.25 mmol/L (12.5 nmol) NMDA reduced the density of αRGCs to 47.4 ± 1.8% and 29.1 ± 3.9% of the non-injected right eyes, respectively (Figures 4C,D). The differences between the NMDA injected eyes and the non-injected eyes are statistically significant in both NMDA concentrations (paired t-test, p < 0.001).

J-RGCs Are Highly Sensitive to NMDA Excitotoxicity

Finally, we examined the susceptibility of J-RGC to NMDA excitotoxicity using JamB:YFP mice. JamB:YFP mice express YFP in two types of J-RGCs with distinctive dendritic morphology, one with an asymmetric DF and another with a more symmetric DF (Kim et al., 2008, 2010). In addition, YFP is also expressed in some amacrine cells located in the INL but not displaced amacrine cells in the GCL (data not shown). In this study, we only count the YFP-expressing cells in the GCL, which includes both types of J-RGCs, but not YFP-expressing cells in the INL. Figure 4E shows a representative image of a JamB:YFP retina (E1) and a magnified view to show the dendritic morphology of the two types of J-RGCs. J-RGCs seem to be extremely sensitive to NMDA excitotoxicity. Figure 4F shows a representative image of a JamB:YFP retina 1 day after intraocular injection of 2 μL 0.75 mmol/L (1.5 nmol) NMDA. In this JamB:YFP retina, the vast majority of J-RGCs lost their dendrites and somas and only retained their axonal processes 1 day after NMDA injection (Figure 4F2, indicated by white arrows). Quantitatively, intraocular injection of 2 μL 0.75 mmol/L (1.5 nmol) or 3.125 mmol/L (6.25 nmol) NMDA reduced the densities of J-RGCs to 9.3 ± 0.7% and 2.1 ± 1.2% in comparison with...
FIGURE 4 | αRGC and J-RGC death in NMDA excitotoxicity. The density YFP-expressing αRGCs and J-RGCs with NMDA injection into left eyes were quantified and normalized to that of non-injected right eyes. 

(A) A magnified view of a Kcng4Crem:YFP mouse retina without NMDA injection to show YFP-expressing αRGCs. 

(B) A magnified view of a Kcng4Crem:YFP mouse retina 24 h after 2 µL 6.25 mmol/L (12.5 nmol) NMDA injection to show the death of αRGCs. 

(C) The normalized survival rates of αRGCs treated with 2 µL 3.125 mmol/L (6.25 nmol) NMDA injection and control eyes. 

(D) The survival rates of αRGCs treated with 6.25 mmol/L (12.5 nmol) NMDA injection and control eyes. 

(E) A representative image of a flat-mount JamB:YFP mouse retina without NMDA injection. 

(F) A representative image of a flat-mount retina of a JamB:YFP mouse 24 h after 0.75 mmol/L (1.5 nmol) NMDA injection 

(G) The normalized survival rates of J-RGCs treated with 2 µL 0.75 mmol/L (1.5 nmol) NMDA injection and control eyes. 

(H) The survival rates of J-RGCs treated with 2 µL 3.125 mmol/L (6.25 nmol) NMDA injection and control eyes. 

The numbers in each column of (C,D,G,H) indicate the number of eyes of each group.

The non-injected right eyes, respectively (Figures 4G,H). The differences between the NMDA injected eyes and the non-injected eyes are highly significant with these two NMDA concentrations (paired t-test, p < 0.001).

The Susceptibility of RGCs to NMDA Excitotoxicity Is Type-Specific

Overall, we examined the susceptibility of four groups of RGCs to NMDA excitotoxicity and the results showed a clear type-specific pattern of RGC death. Of the tested four groups of RGCs, αRGCs seem to be the most resistant RGCs to NMDA excitotoxicity, while J-RGCs are the most sensitive cells to NMDA excitotoxicity (Figures 5A,B). The survival rates of these four groups of RGCs varied from 47.4 ± 1.8% (αRGCs) to 9.3 ± 0.7% (J-RGCs) in response to 2 µL 3.125 mmol/L (6.25 nmol) NMDA. When the results are compared to the collective responses of 12 morphological types of RGCs from the Thy1-YFP mice, the survival rate of αRGCs is very close to that of 12 morphological types of YFP-positive RGCs of Thy1-YFP mice (Figure 5A). Paired tests show that the differences in RGC survival rates between the four groups of NMDA treated RGCs to their non-injected contralateral eyes are statistically significant (paired t-tests).
Christensen et al. RGC Susceptibility to NMDA Toxicity

FIGURE 5 | RGC type-specific susceptibility to NMDA excitotoxicity. The survival rates of YFP-expressing RGCs in Thy1-YFP mice, Kcnq4Cre:YFP mice, TYW3 mice, BD:YFP and JamB:YFP mice 24 h after intraocular injection of 2 µl 3.125 mmol/L (6.25 nmol) NMDA (A) or 2 µl 0.75 mmol/L (1.5 nmol) NMDA (B) were compared to the contralateral control eyes. The number in each column indicates the number of eyes of the group. *** indicates 0.001 > p.

The Kinetics of Dendritic Retraction of RGCs in NMDA Excitotoxicity

It has been postulated that RGCs lose synaptic connections and dendritic processes before death in glaucoma and ONC models (Weber et al., 1998; Shou et al., 2003; Kuehn et al., 2005; Morgan et al., 2006; Leung et al., 2008; Weber et al., 2008; Liu et al., 2011; Della Santina et al., 2013; Feng et al., 2013; Ou et al., 2016). To test whether the extent of RGC dendritic retraction is correlated to the death rate of RGCs in a type-specific manner, we examined the kinetics of dendritic retraction of αRGCs, BD-RGCs and J-RGCs in response to NMDA excitotoxicity using time lapse imaging on an ex vivo retinal preparation (Xu et al., 2010). αRGCs can be easily recognized based on their dendritic pattern in Thy1-YFP mice (Xu et al., 2010). BD-RGCs and J-RGCs are recognized in BD:YFP and JamB:YFP retinas based on their YFP signaling and dendritic pattern (Figure 6A). Our results showed that J-RGCs lost 67% of their dendrites 1 h after 200 nmol/L NMDA application and completely lost all dendrites 2 h after NMDA application for 10 min (Figure 6B). The αRGCs, on the other hand, only lost 38% of their dendrites 1 h after NMDA application for 10 min but still lost all dendrites 7 h after NMDA application. Most noticeably, BD-RGCs lost 36% of their dendrites 1 h after NMDA application for 10 min but still maintained 18% of their dendrites 7 h after NMDA application (Figure 6B). Taken together with the results shown in Figure 5, these results demonstrate that the kinetics of dendritic retraction of RGCs does not correlate to the susceptibility of RGC death due to NMDA excitotoxicity.

DISCUSSION

Our results show that the susceptibility of different types of genetically identified RGCs to NMDA excitotoxicity varies significantly. The αRGCs are the most resistant RGCs to NMDA excitotoxicity while the J-RGCs are the most sensitive RGCs to NMDA excitotoxicity. These results strongly suggest that the differences in the genetic background of RGC types might provide valuable insights for the understanding of the selective vulnerability of RGCs to pathological insults and could assist in the development of strategies for protecting RGCs under disease conditions. In addition, the sequence of the morphological and molecular events during RGC death suggests that the initial insult of NMDA excitotoxicity might set off a cascade of events that is subsequently independent of the primary insults.

Classification of RGC Types

Morphologically, RGCs are classified into about 20 types (Badea and Nathans, 2004; Völgyi et al., 2005; Kim et al., 2008;
Kay et al., 2011), which is closely correlated to the function of RGCs (Cleland et al., 1975). For instance, based on RGC dendritic ramification in the IPL, RGCs are functionally divided into ON, OFF and ON-OFF types. Recent advances in optical imaging methods have provided an efficient way to record RGC light responses for functional classification of RGCs (Briggman and Euler, 2011; Briggman et al., 2011; Baden et al., 2016). More recently, RGCs have been classified into at least 40 types by combining morphological, functional and genetic features (Sanes and Masland, 2015; Rheuame et al., 2018).

This study includes four groups of RGCs with unique structural, functional and genetic features. The BD-RGCs are a type of ON-OFF direction-selective RGCs (DS-RGCs). In mouse retinas, there are four types of ON-OFF DS-RGCs, tuned to motion in ventral, dorsal, nasal, and temporal. BD-RGCs are sensitive to ventral motion (Kim et al., 2010; Trenholm et al., 2011). W3-RGCs are the smallest in size and the most numerous RGCs (Kim et al., 2010). There are at least two types of W3-RGCs: W3B, which are motion sensitive, and W3D, which remain physiologically uncharacterized (Zhang et al., 2012; Kim and Kerschensteiner, 2017). There are at least three types of αRGCs in mouse retinas (Pang et al., 2003; Estevez et al., 2012). Kcnq4Cre:YFP mice express YFP in all three types of αRGCs, and some subsets of bipolar cells (Duan et al., 2015). There are three types of JαB expressing RGCs in mouse retina, which differ in dendritic tree morphology (Kim et al., 2008, 2010; Sanes and Masland, 2015). The JαB:YFP mice express YFP in two types of JαB expressing RGCs (J-RGCs). One type of J-RGCs orients its dendrites toward ventrally to form a polarized DF and is sensitive to directional movement, color-opponent responses, and orientation selective response (Kim et al., 2008, 2010; Joesch and Meister, 2016; Nath and Schwartz, 2017). The second type of J-RGCs has a symmetric DF and the function of them is not well characterized (Kim et al., 2008). In addition, YFP is expressed in about 12 morphological types of RGCs in the Thy1-YFP mice (Xu et al., 2010). Altogether, these transgenic mice provide a total of 8 RGC types individually or in small groups, including 1 DS-RGCs, 2 W3-RGCs, 3 αRGCs, 2 J-RGCs, and a mouse strain for a group of 12 types of RGCs.

NMDA Excitotoxicity in Retinal Diseases
Glutamate excitotoxicity is thought to play a critical role in RGC death in many retinal diseases, such as glaucoma, diabetic retinopathy, optic nerve injury and retinal ischemia (Kuehn et al., 2005; Kwon et al., 2009; Tezel, 2013). Glaucoma is a chronic optic neuropathy characterized by progressive RGC axon degeneration and cell death. One proposed mechanism for glaucomatous damage describes increased pressure in the eye leading to glutamate-induced excitotoxicity. Consistently, elevated IOP increases the expression of NMDARs in DBA/2J mice (Dong et al., 2013) and the numbers of NMDAR positive RGCs are reduced parallel to the loss of RGC in a chronic elevated IOP model (Luo et al., 2009). In addition, a NMDA antagonist, memantine, significantly reduces RGC loss and the expression of NMDARs (WoldeMussie et al., 2002; Sánchez-Lozpez et al., 2018), suggesting that NMDARs are involved in the RGC death in glaucoma. Furthermore, elevated IOP activates NMDARs, which triggers mitochondria-mediated apoptosis through releasing of optic atrophy 1 (OPA1) (Ju et al., 2008). Blockade of glutamate receptor inhibits OPA1 release, increases Bcl-2 expression, decreases Bax expression, and block apoptosis in glaucomatous mouse retina (Ju et al., 2009).

There is an emerging body of evidence that suggests neurodegeneration is a key initial process in the development of diabetic retinopathy (DR) and RGC injury occurs prior to microvascular damage via multiple potential mechanisms including overstimulation of the NMDAR (Smith, 2002; Barber, 2003; Araszkiewicz and Zozulinska-Ziolkiewicz, 2016). For instance, there is an elevated aqueous/vitreous glutamate level in DR animal models and DR patients (Ambati et al., 1997; Kowluru et al., 2001). The immunoreactivities of NRI and GluR2/3 are upregulated in RGCs of both patients with diabetes and experimental DR animals (Ng et al., 2004; Santiago et al., 2008). In addition, blocking of NMDAR protects RGCs against neurodegeneration in DR rats (Kusari et al., 2007).

In ONC models, the NMDA antagonists, memantine and MK-801, protect RGCs from death (Yoles et al., 1997; WoldeMussie et al., 2002). In addition, the AMPA-KA antagonist, DNQX, also protects RGCs after ONC (Schuettauf et al., 2000). Furthermore, MK-801 and other NMDAR antagonists also prevent RGC death by retinal ischemia, reduces the expression of the pro-degeneration gene Bad and significantly increases the pro-survival activity of the PI3K/Akt pathway in the retina (Russo et al., 2008). Therefore, NMDA excitotoxicity seems to participate in RGC death induced by both optic nerve injury and retinal ischemia.

RGC Type-Specific Susceptibility to Retinal Diseases
The type-specific susceptibility of RGCs has been proposed as a factor in several retinal diseases. It has been proposed that the susceptibility of RGCs to glutamate excitotoxicity depends on soma size and retinal eccentricity. Larger RGCs at peripheral retina are more sensitive to kainate excitotoxicity while smaller RGCs at central retina are more sensitive to NMDA excitotoxicity (Vorwerk et al., 1999). In addition, intrinsically photosensitive melanopsin-expressing RGCs (ipRGCs) are also resistant to NMDA excitotoxicity (DeParis et al., 2012; Wang et al., 2018). In animal models of glaucoma, RGCs with large somata or big axon are more vulnerable to elevated IOP (Quigley et al., 1988; Kowluru et al., 2001). The immunoreactivities of NR1 and GluR2/3 are upregulated in RGCs of both ONC models and ONC patients (Schuettauf et al., 2000). In addition, the AMPA-KA antagonist, DNQX, also protects RGCs after ONC (Schuettauf et al., 2000). Furthermore, MK-801 and other NMDAR antagonists also prevent RGC death by retinal ischemia, reduces the expression of the pro-degeneration gene Bad and significantly increases the pro-survival activity of the PI3K/Akt pathway in the retina (Russo et al., 2008). Therefore, NMDA excitotoxicity seems to participate in RGC death induced by both optic nerve injury and retinal ischemia.
the transient OFF αRGCs exhibited higher rate of cell death, while neither sustained OFF αRGCs nor sustained ON αRGCs have reduced synaptic activity due to elevated IOP (Ou et al., 2016). Similar to models with elevated IOP, OFF RGCs were more susceptible than ON RGCs to ONC, and ON sustained RGCs seem to be more susceptible than ON transient RGCs to ONC (Puyang et al., 2017). Among αRGCs, ipRGCs, DSRGCs and W3-RGCs, αRGCs seem to be the least susceptible type to ONC (Duan et al., 2015). These results are consistent with our observation in this study and support the notion that glutamate excitotoxicity could play critical roles in RGC death of optic nerve injury.

Inconsistent with some previous reports, our results do not provide a clear correlation between RGC morphology and susceptibility to NMDA excitotoxicity. Among the 4 groups of genetically identified RGCs tested in this study, their susceptibility to NMDA excitotoxicity seems not directly correlate to the size of their soma and DF. This is evident that both BD-RGCs and J-RGCs have much higher susceptibility to NMDA excitotoxicity than αRGCs, which are known to have the biggest size of soma and DF, and W3-RGCs, which are the RGCs with the smallest size of soma and DF (Kim et al., 2010). This is opposite to the observations by several previous studies (Quigley et al., 1988; Glovinsky et al., 1991; Vorwerk et al., 1999). It was also reported that OFF RGCs appear to be more vulnerable to elevated IOP and ONC than ON RGCs (Della Santina et al., 2013; El-Danaf and Huberman, 2015; Ou et al., 2016; Della Santina and Ou, 2017; Puyang et al., 2017; Sabharwal et al., 2017), while ON RGCs are more susceptible to elevated IOP than ON-OFF RGCs (Feng et al., 2013). However, the ON and OFF inputs seem not play a critical role in NMDA-induced RGC death to BD-RGCs, which are ON-OFF RGCs (Kim et al., 2010; Trenholm et al., 2011), and J-RGCs, which are OFF-RGCs (Kim et al., 2008, 2010; Joesch and Meister, 2016; Nath and Schwartz, 2017).

An important question is what the underlying reasons contribute to these inconsistent observations. At least two important factors might play significant roles to this RGC type-specific susceptibility: the way how the RGC types are determined and the types of pathological insults. RGCs have been classified into types based on morphological, functional and genetic properties (Cleland et al., 1975; Badea and Nathans, 2004; Völgyi et al., 2005; Kim et al., 2008; Briggman and Euler, 2011; Braggman et al., 2011; Kay et al., 2011; Sanes and Masland, 2015; Baden et al., 2016; Rheuame et al., 2018). Most previous studies of RGC type-specific susceptibility are based on morphological and functional classification (Quigley et al., 1988; Glovinsky et al., 1991; Vorwerk et al., 1999; Della Santina et al., 2013; Feng et al., 2013; El-Danaf and Huberman, 2015; Ou et al., 2016; Della Santina and Ou, 2017; Puyang et al., 2017; Sabharwal et al., 2017). Because these morphologically and functionally classified RGC types are likely to have heterogeneous gene expression profiles and, if the gene expression profiles of RGCs contribute to the type-specific susceptibility, how the RGCs are grouped into types could have significant influence on the observed susceptibility.

Although very few studies have directly compared the susceptibility of the same type of RGCs to different pathological insults, it is plausible to assume that the underlying molecular mechanisms of RGC death induced by different pathological insults might be different due to the nature of insults, such as NMDA excitotoxicity elevates intracellular calcium while ONC reduces axonal transportation. Therefore, the susceptibility of the same type of RGCs might vary significantly to different types of pathological insults. Consistent with this idea, our unpublished data of an ongoing study demonstrate that the susceptibility of the four types RGCs tested in this study varies dramatically with types of injuries. In responding to ONC, BD-RGCS have the lowest susceptibility while W3-RGCs have the highest susceptibility, which is opposite to the ranking of susceptibility to NMDA excitotoxicity. Therefore, we propose that the susceptibility of different types of RGCs is likely to be determined by an interaction between the pathological insults and cell intrinsic response mechanisms. Different types of injuries might trigger different intrinsic response mechanisms in different types of RGCs, which might have different efficacy in activation of the cell death processes in different types of RGCs. If this is a general rule for type-specific RGC death in retinal diseases, it may not be reliable to predict the pattern of RGC death in one disease based on patterns of other diseases.

The Sequence of RGC Degeneration

Retinal ganglion cells lose synapses prior to a reduction in synaptic activity, leading to dendritic shrinkage and eventually cell death in glaucoma models of primates, cats, rats and human patients and animal models of ONC (Weber et al., 1998; Shou et al., 2003; Kuehn et al., 2005; Morgan et al., 2006; Leung et al., 2008; Weber et al., 2008; Liu et al., 2011; Della Santina et al., 2013; Feng et al., 2013; Ou et al., 2016). Carefully studying the sequence of structural, functional and molecular changes of injured RGCs could provide critical insights into the underlying mechanisms of RGC death and shed light on potential treatments aimed at reversing or slowing RGC degeneration. The present study demonstrates that many RGCs that lost all of their dendrites remained CASP3-negative while hardly any RGCs expressed CASP3 before completely losing their dendrites. The sequence of these morphological and molecular events suggests that the initial insult of NMDA excitotoxicity might only induce the loss of RGC dendrites through altering of the synaptic activity. Because this sequence of events seems to be consistent across several different experimental disease models, the initial insult in retinal diseases may set off a cascade of events that is subsequently independent of the primary insults. Regardless the underlying mechanisms, the kinetics of dendritic retraction of RGCs does not directly correlate to the susceptibility of type-specific RGC death. Because RGCs lose dendrites prior to cell death, using the dendritic morphology, the ramification patterns of RGC dendrites or patterns of light responses of RGCs to identify types of the cells under disease conditions might be misleading. The use of genetic markers provides a more reliable approach to identify
the types of RGC under disease conditions. Therefore, our results provide valuable insights into the type-specific susceptibility of RGCs to NMDA excitotoxicity.

DATA AVAILABILITY

All datasets generated for this study are included in the manuscript and/or the supplementary files.

AUTHOR CONTRIBUTIONS

IC and NY collected and analyzed the data and prepared the manuscript. BL and KH collected and analyzed the data. PW contributed the animal preparation and resource management. NT designed the experiments, analyzed the data, prepared the manuscript, and managed the research fund.

REFERENCES

Almasieh, M., Wilson, A. M., Morquette, B., Cueva Vargas, J. L., and Di Polo, A. (2012). The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye Res. 31, 152–181. doi: 10.1016/j.preteyeres.2011.11.002

Ambati, J., Chalam, K. V., Chawla, D. K., D’Angio, C. T., Guillet, E. G., Rose, S. J., et al. (1997). Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmal. 115, 1161–1166. doi: 10.1001/archoph.1997.0100160331011

Araszkiewicz, A., and Zozulinaka-Ziolikiewicz, D. (2016). Retinal neurodegeneration in the course of diabetes-pathogenesis and clinical perspective. Curr. Neuropharmacol. 14, 805–809. doi: 10.2174/1570159X1466610023154536

Badea, T. C., and Nathans, J. (2004). Quantitative analysis of neuronal morphologies in the mouse retina visualized by using a genetically directed reporter. J. Comp. Neurol. 480, 331–351. doi: 10.1002/cne.20304

Baden, T., Berens, P., Franke, K., Römö Rosón, M., Bhethge, M., and Euler, T. (2016). The functional diversity of retinal ganglion cells in the mouse. Nature 529, 345–350. doi: 10.1038/nature16468

Bai, N., Aida, T., Yanagisawa, M., Katou, S., Sakimura, K., Mishina, M., et al. (2013). NMDA receptor subunits have different roles in NMDA-induced neurotoxicity in the retina. Mol. Brain 6:34. doi: 10.1186/1756-6606-6-34

Barber, A. J. (2003). A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 283–290.

Briggman, K. L., and Euler, T. (2011). Bulk electroporation and population calcium imaging in the adult mammalian retina. J. Neurophysiol. 105, 2601–2609. doi: 10.1152/jn.00722.2010

Briggman, K. L., Helmstaedter, M., and Denk, W. (2011). Wiring specificity in the direction-selectivity circuit of the retina. Nature 471, 183–188. doi: 10.1038/nature09818

Camacho, A., and Massieu, L. (2006). Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death. Arch. Med. Res. 37, 11–18. doi: 10.1016/j.arcmed.2005.05.014

Cleland, B. G., Levick, W. R., and Wässle, H. (1975). Physiological identification of a morphological class of cat retinal ganglion cells. J. Physiol. 248, 151–171. doi: 10.1113/jphysiol.1975.sp00967

Daniel, S., Clark, A. F., and McDowell, C. M. (2018). Subtype-specific response of retinal ganglion cells to optic nerve crush. Cell Death Discov. 4:67. doi: 10.1038/s41420-018-0069-y

Della Santina, L., Inman, D. M., Lupien, C. B., Horner, P. J., and Wong, R. O. (2013). Differential progression of structural and functional alterations in distinct retinal ganglion cell types in a mouse model of glaucoma. J. Neurosci. 33, 17444–17457. doi: 10.1523/JNEUROSCI.5461-12.2013

Della Santina, L., and Ou, Y. (2017). Who’s lost first? Susceptibility of retinal ganglion cell types in experimental glaucoma. Exp. Eye Res. 158, 43–50. doi: 10.1016/j.exer.2016.06.006

DeParis, S., Caprara, C., and Grimm, C. (2012). Intrinsically photosensitive retinal ganglion cells are resistant to N-methyl-D-aspartic acid excitotoxicity. Mol. Vis. 18, 2814–2827.

Dong, L. D., Chen, J., Li, F., Gao, F., Wu, J., Miao, Y., et al. (2013). Enhanced expression of NR2B subunits of NMDA receptors in the inherited glaucomatous DBA/2J mouse retina. Neural Plast. 2013:670254. doi: 10.1155/2013/670254

Duan, X., Qiao, M., Bei, F., Kim, I. J., He, Z., and Sanes, J. R. (2015). Subtype-specific regeneration of retinal ganglion cells following axotomy: effects of osteopontin and mTOR signaling. Neuron 85, 1244–1256. doi: 10.1016/j.neuron.2015.02.017

Dutta, R., and Trapp, B. D. (2011). Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog. Neurobiol. 93, 1–12. doi: 10.1016/j.pneurobio.2010.09.005

El-Danaf, R. N., and Huberman, A. D. (2015). Characteristic patterns of dendritic remodeling in early-stage glaucoma: evidence from genetically identified retinal ganglion cell types. J. Neurosci. 35, 2329–2343. doi: 10.1523/JNEUROSCI.1419-14.2015

Estevez, M. E., Fogerson, P. M., Iardi, M. C., Borghuis, B. G., Chan, E., Weng, S., et al. (2012). Form and function of the M4 cell, an intrinsically photosensitive retinal ganglion cell type contributing to geniculocortical vision. J. Neurosci. 32, 13608–13620. doi: 10.1523/JNEUROSCI.1422-12.2012

Evangelho, K., Mogilevskaya, M., Losada-Barragan, M., and Vargas-Sanchez, J. K. (2017). Pathophysiology of primary open-angle glaucoma from a neuroinflammatory and neurotoxicity perspective: a review of the literature. Int. Ophthalmol. doi: 10.1007/s10792-017-0795-9 [Epub ahead of print].

Feng, L., Zhao, Y., Yoshida, M., Chen, H., Yang, J. F., Kim, T. S., et al. (2013). Sustained ocular hypertension induces dendritic degeneration of mouse retinal ganglion cells that depends on cell type and location. Invest. Ophthalmol. Vis. Sci. 54, 1106–1117. doi: 10.1177/0014600612473030

Fletcher, E. L., Hack, I., Brandstatter, J. H., and Wasse, H. (2000). Synaptic localization of NMDA receptor subunits in the rat retina. J. Comp. Neurol. 420, 98–112. doi: 10.1002/(SICI)1096-9861(20000424)420:1<98::AID-CNE7>3.0.CO;2-U

Glovisky, Y., Quigley, H. A., and Dunkelberger, G. R. (1991). Retinal ganglion cell loss is size dependent in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 32, 484–491.

Hardingham, G. E., Fukunaga, Y., and Bading, H. (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 405–414. doi: 10.1038/nn835

Huang, Z., Zang, K., and Reichardt, L. F. (2005). The origin recognition core complex regulates dendrite and spine development in postmitotic neurons. J. Cell Biol. 170, 527–535. doi: 10.1083/jcb.200505075

Hulsebosch, C. E., Hains, B. C., Crown, E. D., and Carlton, S. M. (2009). Mechanisms of chronic central neuropathic pain after spinal cord injury. Brain Res. Rev. 60, 202–213. doi: 10.1016/j.brainresrev.2008.12.010

Ishimaru, Y., Sumino, A., Kajioka, D., Shibagaki, F., Yamamuro, A., Yoshioka, Y., et al. (2017). Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α

FUNDING

This work was supported by the Department Veterans Affair (1I01BX002412-01A2), the National Eye Institute (R01EY012345 and EY014800), and Research to Prevent Blindness (RPB). This work was also supported by the National Institutes of Health under Ruth L. Kirschstein National Research Service Award (T35EY026511) from the National Eye Institute and a Medical Student Summer Research Scholarship from American Academy of Neurology.
Stavrovskaya, I. G., and Kristal, B. S. (2005). The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death? Free Radic. Biol. Med. 38, 687–697.

Tezel, G. (2013). Immune regulation toward immunomodulation for neuroprotection in glaucoma. Curr. Opin. Pharmacol. 13, 23–31. doi: 10.1016/j.coph.2012.09.013

Trenholm, S., Johnson, K., Li, X., Smith, R. G., and Awatramani, G. B. (2011). Parallel mechanisms encode direction in the retina. Neuron 71, 683–694. doi: 10.1016/j.neuron.2011.06.020

Völgyi, B., Abrams, J., Paul, D. L., and Bloomfield, S. A. (2005). Morphology and tracer coupling pattern of alpha ganglion cells in the mouse retina. J. Comp. Neurol. 492, 66–77. doi: 10.1002/cne.20700

Vorwerk, C. K., Kreutz, M. R., Böckers, T. M., Brosz, M., Dreyer, E. B., and Sabel, B. A. (1999). Susceptibility of retinal ganglion cells to excitotoxicity depends on soma size and retinal eccentricity. Curr. Eye Res. 19, 59–65. doi: 10.1076/ceyr.19.1.5.5336

Wang, S., Gu, D., Zhang, P., Chen, J., Li, Y., Xiao, H., et al. (2018). Melanopsin-expressing retinal ganglion cells are relatively resistant to excitotoxicity induced by N-methyl-d-aspartate. Neosci. Lett. 662, 368–373. doi: 10.1016/j.neulet.2017.10.055

Weber, A. J., Harman, C. D., and Viswanathan, S. (2008). Effects of optic nerve injury, glaucoma, and neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina. J. Physiol. 586, 4393–4400. doi: 10.1113/jphysiol.2008.156729

Weber, A. J., Kaufman, P. L., and Hubbard, W. C. (1998). Morphology of single ganglion cells in the glaucomatous primate retina. Invest. Ophthalmol. Vis. Sci. 39, 2304–2320.

Williams, P. A., Howell, G. R., Barbay, J. M., Braine, C. E., Sousa, G. L., and John, S. W. (2013). Retinal ganglion cell dendritic atrophy in DBA/2J glaucoma. PLoS One 8:e72282. doi: 10.1371/journal.pone.0072282

WoldeMussie, E., Yoles, E., Schwartz, M., Ruiz, G., and Wheeler, L. A. (2002). Neuroprotective effect of memantine in different retinal injury models in rats. J. Glaucoma 11, 474–480. doi: 10.1097/00061198-200212000-00003

Xu, H. P., Chen, H., Ding, Q., Xie, Z. H., Chen, L., Diao, L., et al. (2010). The immune protein CD3ζ is required for normal development of neural circuits in the retina. Neuron 65, 503–515. doi: 10.1016/j.neuron.2010.01.035

Yoles, E., Muller, S., and Schwartz, M. (1997). NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. J. Neurotrauma 14, 665–675. doi: 10.1089/neu.1997.14.665

Zhang, J., and Diamond, J. S. (2009). Subunit- and pathway-specific localization of NMDA receptors and scaffolding proteins at ganglion cell synapses in rat retina. J. Neurosci. 29, 4274–4286. doi: 10.1523/JNEUROSCI.5602-08.2009

Zhang, Y., Kim, I. J., Sanes, J. R., and Meister, M. (2012). The most numerous ganglion cell type of the mouse retina is a selective feature detector. Proc. Natl. Acad. Sci. U.S.A. 109, E2391–E2398. doi: 10.1073/pnas.1211547109

Zhao, J., Mysona, B. A., Qureshi, A., Kim, L., Fields, T., Gonsalvez, G. B., et al. (2016). (+)-pentazocine reduces NMDA-induced murine retinal ganglion cell death through a σR1-dependent mechanism. Invest. Ophthalmol. Vis. Sci. 57, 453–461. doi: 10.1167/iovs.15-18565

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.